GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Total Receivables

Zai Lab (HKSE:09688) Total Receivables : HK$593 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Total Receivables?

Zai Lab's Total Receivables for the quarter that ended in Mar. 2024 was HK$593 Mil.


Zai Lab Total Receivables Historical Data

The historical data trend for Zai Lab's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Total Receivables Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only 29.59 40.04 427.46 378.15 510.24

Zai Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 476.63 533.15 511.01 510.24 592.87

Zai Lab Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Zai Lab Total Receivables Related Terms

Thank you for viewing the detailed overview of Zai Lab's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (HKSE:09688) Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Zai Lab (HKSE:09688) Headlines

No Headlines